VIVOS Business Summary

Vivos Inc (RDGL) is a radiation oncology medical device company specializing in Precision Radionuclide Therapy (PRnT) for the treatment of non-resectable solid tumors. The company generates revenue through the direct sale of its proprietary brachytherapy devices, primarily segmented into its veterinary division, IsoPet, and its human clinical division, RadioGel. IsoPet is currently in an active commercialization phase, generating revenue through a growing network of certified veterinary clinics and strategic partnerships, such as its collaboration with Exubrion Therapeutics. Meanwhile, RadioGel is positioned in the pre-commercial stage as the company pursues FDA Investigational Device Exemption (IDE) for human clinical trials. Vivos competes with firms like PetVivo Holdings, Sirtex Medical, and IsoRay, distinguishing itself through its injectable hydrogel technology that delivers localized beta radiation with minimal systemic migration or damage to healthy tissue. The leadership team is anchored by CEO Dr. Michael K. Korenko, an MIT-trained scientist and former White House Fellow with over 30 patents in nuclear and materials science. In September 2025, the executive team was expanded with the appointments of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer; Weeks brings a background in medical device regulatory affairs from Cadwell Industries, while Swanberg is a co-founder of IsoRay with over 35 years of experience in radiochemical processing. The Board of Directors is chaired by Dr. Carlton Cadwell, the founder of Cadwell Laboratories and a veteran in the neurodiagnostic device industry. To bolster its regulatory strategy, the company has also engaged Dr. John J. Smith, a former FDA official, to oversee its IDE submissions and clinical expansion into international markets, including the newly formed Vivos Scientific India LLP.